Quince Therapeutics (QNCX) Other Non-Current Liabilities (2023 - 2026)

Quince Therapeutics has reported Other Non-Current Liabilities for 4 years, with the latest figure at $6.3 million in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 89.36% year-over-year to $6.3 million in Q2 2026; TTM through Jun 2026 was $6.3 million, a 89.36% decrease from a year earlier, with the FY2025 full-year figure at $52.0 million, down 8.34% from the prior year.
• Other Non-Current Liabilities was $6.3 million for Q2 2026 at Quince Therapeutics, up from $1.2 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $73.8 million in Q1 2024, with the low at $1.2 million in Q1 2026.
• Average Other Non-Current Liabilities over 4 years is $49.4 million, with a median of $57.7 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities grew 11.73% in 2025, then tumbled 97.96% in 2026.
• Over 4 years, Other Non-Current Liabilities stood at $57.7 million in 2023, then dropped by 1.76% to $56.7 million in 2024, then dropped by 8.34% to $52.0 million in 2025, then sank by 87.89% to $6.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $6.3 million (Q2 2026), $1.2 million (Q1 2026), and $52.0 million (Q4 2025), per Business Quant data.